To date, the JAK1 inhibitor itacitinib is under evaluation in combination with pembrolizumab for advanced solid tumors, including PC, following encouraging results of the phase Ib/II trial testing this drug in combination with nab-paclitaxel and gemcitabine [97]. The gene discussed is JAK1; the disease is pachyonychia congenita.